Phentermine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Phentermine (2-methyl-1-phenylpropan-2-amine) is a synthetic stimulant of the phenethylamine class. It is a modified form of amphetamine, distinguished by reduced dopaminergic potency and lower abuse potential.[1] Phentermine is a norepinephrine releasing agent, producing its effects by flooding hypothalamic appetite circuits with norepinephrine.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Phentermine received FDA approval in 1959 as a short-term appetite suppressant, one of the earliest amphetamine-class anorectics to reach market.[3] Its trajectory was defined by the fen-phen crisis of 1997, when fenfluramine's serotonergic valvular toxicity led to withdrawal — phentermine was exonerated and remained available.[4] It is the most commonly prescribed obesity medication in the United States as of 2026.
Subjective effects include appetite suppression, wakefulness, psychomotor activation, and mild mood elevation. The experience is functional rather than euphoric — a sustained, flat stimulation dominated by noradrenergic arousal without the rewarding rush characteristic of potent dopamine releasers.[5] Insomnia, dry mouth, elevated heart rate, and restlessness are characteristic unsought effects.
Phentermine carries low abuse liability — abrupt cessation does not produce amphetamine-like withdrawal or cravings.[6] Cardiovascular toxicity is the principal concern: sympathomimetic load elevates heart rate and blood pressure, and pulmonary hypertension has been reported after five weeks of monotherapy.[7] Despite over six decades on market, no completed long-term monotherapy trial existed prior to the ongoing LEAP trial, leaving the chronic cardiovascular risk profile incompletely characterised.[8]
History[edit]
Discovery
Phentermine was synthesised in the early twentieth century through systematic modification of the amphetamine scaffold — a second methyl group added at the alpha-carbon produced an achiral molecule with attenuated dopaminergic activity.[1] The identity of the original synthesist and precise date of first preparation remain unconfirmed.citation needed In 1959, the FDA approved phentermine as a short-term appetite suppressant, and it entered the market alongside other amphetamine-class anorectics including diethylpropion and benzphetamine.[3]
The fen-phen crisis
In 1992, Weintraub and colleagues published a landmark trial combining phentermine with fenfluramine, demonstrating significantly greater weight loss than placebo over 34 weeks.[9] The combination — known as "fen-phen" — became enormously popular, with over 18 million prescriptions filled annually by 1996.[4] In 1997, reports of valvular heart disease linked to fenfluramine's serotonergic mechanism led to fenfluramine's withdrawal; phentermine, which lacked the causative serotonergic activity, was exonerated.[4][10]
Modern era
The European Commission banned phentermine across the EU in 2000–2001, while the United States maintained approval — a regulatory divergence that persists as of 2026. In 2012, the FDA approved phentermine/topiramate (Qsymia) for chronic weight management, the first new obesity drug in 13 years.[11] Phentermine monotherapy remains the most prescribed obesity medication in the US, and the LEAP trial — the first 24-month randomised controlled trial for phentermine monotherapy — is actively underway.[8]
The name "phentermine" derives from its chemical identity: phenyl-tertiary-butyl-amine, compressed into a single word. The compound's cultural identity is inseparable from its association with "fen-phen," which became synonymous with pharmaceutical scandal in the late 1990s — despite phentermine itself being exonerated. In clinical practice, it is known primarily by the brand name Adipex-P, and in weight-loss communities by the informal shorthand "phen."
Chemistry[edit]
Structural class
Phentermine belongs to the amphetamine family of substituted phenethylamines. The parent scaffold is phenethylamine — a two-carbon chain linking a phenyl ring to a terminal amine. Amphetamine adds one methyl group at the alpha-carbon; phentermine adds a second, converting the alpha-carbon into a quaternary centre.[1] This modification eliminates chirality and substantially reduces dopaminergic potency while preserving noradrenergic releasing activity.[2]
Molecular properties
| Molecular formula | C₁₀H₁₅N |
| Molecular weight | 149.23 g/mol |
Stereochemistry
Phentermine is achiral. Unlike amphetamine, whose alpha-carbon bears one methyl group and one hydrogen — creating a stereocentre with distinct levo- and dextro-enantiomers — phentermine's alpha-carbon carries two identical methyl groups.[1] The molecule has no optical activity and is marketed as a single chemical entity. This achirality is pharmacologically significant: phentermine lacks the potent dopaminergic properties associated with specific amphetamine enantiomers, particularly dextroamphetamine.
Physical properties
Phentermine hydrochloride is a water-soluble white crystalline solid.[12] The free base is sufficiently lipophilic to cross the blood–brain barrier readily. Two pharmaceutical forms have been marketed: the hydrochloride salt (Adipex-P 37.5 mg tablets and capsules; Lomaira 8 mg tablets) for rapid absorption, and a discontinued resin formulation (Ionamin) providing slower absorption.[13]
Pharmacology[edit]
Mechanism of action
Phentermine enters nerve terminals via monoamine transporters and triggers the release of stored catecholamines — primarily norepinephrine, with weaker dopamine release and minimal serotonin activity.[2] This norepinephrine-dominant profile is the key distinction from amphetamine, which releases dopamine far more potently.
The released norepinephrine acts on adrenergic receptors in hypothalamic feeding circuits — the lateral hypothalamus and paraventricular nucleus — to suppress appetite and reduce caloric intake.[14] The FDA label describes phentermine as "a sympathomimetic amine with pharmacologic activity similar to amphetamine," while noting that its precise mechanism in weight management remains incompletely established.[3] Its overall pharmacological action has been characterised as "comparable to that of amphetamine albeit less strong".[13]
At clinical doses, PET imaging in primates shows no measurable dopamine release in the striatum — the brain region most associated with reward and addiction — whereas amphetamine at equivalent doses produces robust release.[5] This dissociation between norepinephrine and dopamine activity accounts for phentermine's lower abuse potential and its classification as Schedule IV rather than Schedule II.
Pharmacokinetics
Phentermine is nearly completely absorbed after oral administration, with bioavailability approaching 100%.[12][3] Peak blood levels occur 1–3 hours after ingestion for the hydrochloride salt and approximately 6 hours for the resin formulation. Protein binding is low (17.5%), and the drug distributes extensively into tissues.
The plasma half-life ranges from 16 to 31 hours, but varies substantially with urinary pH: acidic urine accelerates elimination, while alkaline urine prolongs it.[12] This pH dependence is clinically significant — diet, kidney function, and co-medications all influence how long phentermine remains active in the body.
Phentermine undergoes limited liver processing. The majority is excreted unchanged in urine (62–85% of a dose).[12][13] Because it is not extensively metabolised, drug interactions through liver enzyme competition are minimal.citation needed
Neuroscience[edit]
Where it acts
Phentermine's primary neural target is the hypothalamic noradrenergic appetite network. Released norepinephrine acts on adrenergic receptors in the lateral hypothalamus and paraventricular nucleus — structures that integrate hunger and satiety signals from peripheral hormones like leptin and ghrelin.[14] This shifts the balance toward satiety, reducing both meal initiation and meal size.
In the reward system, phentermine's footprint is notably light. PET imaging in primates shows no measurable dopamine release in the striatum at clinical doses,[5] distinguishing it from amphetamine. Rodent recordings reveal that phentermine does modulate nucleus accumbens activity through indirect dopaminergic signalling,[15] but this appears insufficient to drive compulsive use.
Tolerance and sensitisation
The dominant neuroplastic response to phentermine is functional tolerance: the appetite-suppressing effect diminishes within weeks of continuous use.[3] The mechanism is uncharacterised — candidate explanations include downregulation of hypothalamic adrenergic receptors and depletion of norepinephrine stores. Whether phentermine produces the behavioural sensitisation seen with amphetamine (a progressive increase in stimulant response linked to addiction vulnerability) has not been studied.
Several questions remain unanswered. The mechanism driving rapid anorectic tolerance is unknown. Whether phentermine produces structural neuroplastic changes — as amphetamine does in reward-circuit neurons — has not been investigated, a question bearing directly on long-term use safety. The relationship between urinary pH variability, individual drug exposure, and tolerance development has never been studied.
Subjective Effects[edit]
Phentermine produces a mild, sustained stimulant experience dominated by noradrenergic activation. Appetite suppression is the defining effect — a consistent, background reduction in hunger that persists throughout the drug's long duration. Wakefulness and peripheral sympathomimetic arousal accompany the anorectic effect, along with elevated heart rate and a mild blood pressure increase. At higher doses, restlessness and insomnia become more prominent, but the experience remains functional rather than euphoric across the clinical dose range. Set and setting exert minimal influence compared to serotonergic compounds.
Compared to amphetamine, phentermine produces a flatter, less rewarding experience with no measurable central dopamine release at clinical doses — the "high" associated with classical stimulants is largely absent. Relative to caffeine, phentermine is a more potent appetite suppressant with a longer duration and a more pronounced cardiovascular burden, but a qualitatively similar wakefulness profile.
Effect Grid
At 15–37.5 mg oral, the full therapeutic profile emerges. Appetite suppression is pronounced — hunger signals are substantially blunted, and caloric intake decreases meaningfully. Wakefulness is sustained throughout the day, and mild cognitive euphoria or mood brightening may be present, though far less intense than with amphetamine. Focus enhancement and motivation enhancement are noticeable but modest.
Dry mouth is the most frequently reported physical effect. Stimulation is clear: elevated heart rate, mild blood pressure increase, and occasional restlessness or fidgetiness. Constipation occurs in a minority of users. Headache and trembling are possible but uncommon.
Insomnia is likely if the dose is taken after midday. This is the standard clinical range — effects last 8–14 hours subjectively, with residual wakefulness extending further due to the 16–31 hour half-life. Tolerance to the anorectic effect typically develops within a few weeks of continuous use.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dry mouth · Insomnia · Pupil dilation · Heart rate perception changes · Restlessness · Constipation · Dehydration sensation · Excessive sweating · Headache · Dizziness · Muscle tension · Nausea · Trembling · Bruxism
Restlessness · Constipation · Dehydration sensation · Excessive sweating · Headache · Dizziness · Muscle tension · Nausea · Trembling · Bruxism
Confusion
Disinhibition
Timeline
Initial absorption with minimal subjective awareness. A faint sense of alertness may emerge toward the end of this phase.
Rising sympathomimetic activation becomes noticeable. Appetite begins to diminish and wakefulness increases steadily. Heart rate may rise slightly.
Maximum anorectic and stimulant effects. Appetite suppression is pronounced, wakefulness is sustained, and dry mouth is common. Mild mood brightening may be present.
Sustained therapeutic effect at slightly reduced intensity. Appetite suppression is maintained and stimulation continues but feels less acute. Functional performance is preserved.
Gradual waning of stimulant effects. Appetite may partially return. Wakefulness persists but the driven quality diminishes.
Residual wakefulness and mild alertness persist due to the long plasma half-life (16–31 hours). Insomnia is possible if the dose was taken after midday.
⚠ Do not drive if experiencing dizziness or overstimulation.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- amphetamine · methamphetamine · MDMA
Toxicity
Acute toxicity
Phentermine overdose produces a sympathomimetic toxidrome: agitation, dangerously elevated body temperature, and high blood pressure.[12] Severe cases can progress to seizures, stroke, muscle breakdown leading to kidney failure, irregular heart rhythms, and coma.
No human lethal dose has been established. References to fatal doses "as low as 1.3 mg/kg" likely derive from amphetamine-class data and have not been verified as phentermine-specific.safety citation needed Toxicity thresholds vary enormously with tolerance: signs can appear at blood concentrations of approximately 20 µg/L, while chronic users have survived concentrations up to 3,000 µg/L[12] — a 150-fold range.
Population-level data from Tennessee (2019–2022) identified phentermine in fatal overdose toxicology reports, but in most cases it appeared alongside other substances — consistent with polydrug overdose rather than phentermine alone causing death.[16]
For phentermine overdose: contact Poison Control (US: 1-800-222-1222). Treatment is supportive — airway stabilisation, heart rhythm monitoring, benzodiazepines for agitation and seizures, active cooling for dangerously elevated body temperature, IV fluids for muscle breakdown. Urinary acidification can accelerate elimination. Avoid beta-blockers alone — they may worsen high blood pressure through unopposed alpha-adrenergic stimulation.[12][3]
Cardiovascular toxicity
Cardiovascular events are the principal safety concern. A case report describes pulmonary hypertension developing in a 29-year-old woman after just 5 weeks of phentermine monotherapy — the first reported case without fenfluramine involvement.[7]
The fen-phen era demonstrated that valvular heart disease was caused by fenfluramine's serotonergic mechanism, not by phentermine.[4][10] An analysis of the FDA's adverse event reporting database evaluated cardiovascular safety signals for currently marketed anti-obesity drugs including phentermine.[17]
Phentermine is absolutely contraindicated in coronary artery disease, stroke, irregular heart rhythms, heart failure, and uncontrolled high blood pressure.[3]
Psychological risks
Psychosis is listed as a rare adverse effect on the FDA prescribing label.[3] Case reports associate phentermine with severe psychiatric outcomes including dangerously elevated blood pressure and exacerbation of existing mental illness.[13] At doses above the prescribed range or in predisposed individuals, phentermine can trigger psychosis, delirium, and severe agitation.
Risk factors include pre-existing psychotic disorders, bipolar disorder, concurrent stimulant use, and use above prescribed doses. The prescribing label contraindicates phentermine in "agitated states".[3]
Tolerance and dependence
Tolerance to phentermine's appetite-suppressing and stimulant effects develops within weeks of continuous use. The FDA label directs discontinuation rather than dose escalation when tolerance appears.[3] In the Weintraub fen-phen trial series, some tolerance to the combination was documented over the 4-year study period.[18]
Dependence liability is low. In a study of 35 patients who abruptly stopped long-term phentermine, withdrawal severity scores were not significantly different from people who had never taken the drug — and were strikingly different from amphetamine-dependent individuals.[6] Cravings, the hallmark of substance dependence, were entirely absent.
Phentermine produced recognisable stimulant-like subjective effects in a controlled study using stimulant-preferring drug users, but at lower intensity than methylphenidate.[19] A larger investigation into addiction potential of long-term phentermine treatment has been published.[20] Cross-tolerance with other catecholamine-releasing agents (amphetamine, methamphetamine, MDMA) is probable based on shared mechanism but has not been directly studied.
Drug interactions
MAOI interaction (absolute contraindication): Use within 14 days of a monoamine oxidase inhibitor is absolutely contraindicated. MAOIs prevent the breakdown of released norepinephrine and dopamine; combined with phentermine's catecholamine release, this can produce a potentially fatal hypertensive crisis.[3]
SSRI/SNRI interaction: serotonin syndrome is a theoretical risk. A survey of 1,174 patients taking phentermine with SSRIs found zero cases,[21] but a 2025 case report documents serotonin syndrome with multi-organ injury from an anti-obesity and antidepressant combination.[22] Clinical monitoring is warranted when these agents are combined.
Other stimulants: Co-administration with other catecholamine releasers (amphetamine, MDMA, cocaine) would be expected to produce additive sympathomimetic toxicity.safety citation needed
Blood pressure medications: Phentermine may reduce the effectiveness of blood-pressure-lowering drugs through pharmacological antagonism.[3] Conversely, phentermine-induced weight loss can lower systolic blood pressure by 7.5–11.8 mmHg in those with high blood pressure, potentially requiring dosage reduction of existing medications.[23]
Insulin and diabetes medications: Phentermine-induced weight loss alters insulin sensitivity and may reduce insulin requirements, necessitating dose adjustment to prevent dangerously low blood sugar.[3]
pH-modifying agents: Urinary acidifiers (ammonium chloride) accelerate phentermine clearance, while urinary alkalinisers (sodium bicarbonate) prolong its half-life.[12]
Fenfluramine (historical): Phentermine did not significantly potentiate fenfluramine-induced serotonin depletion in mouse brain at doses far exceeding clinical use.[24]
Drug testing: Phentermine produces positive results on standard amphetamine urine drug screens. Confirmatory GC-MS or LC-MS/MS testing is required to distinguish it from methamphetamine or amphetamine.[13] Detection window is approximately 2–4 days at standard doses.
Contraindications
The following contraindications are derived from the FDA prescribing information[3]:
Absolute contraindications:
- Concurrent or recent MAOI use (within 14 days)
- Cardiovascular disease: coronary artery disease, stroke, irregular heart rhythms, heart failure, uncontrolled high blood pressure
- Overactive thyroid: excess thyroid hormone amplifies cardiovascular stimulant effects
- Glaucoma: pupil dilation can trigger acute angle-closure crisis
- Agitated states: stimulation may worsen psychiatric instability
- History of drug abuse: phentermine produces recognisable stimulant effects in substance users[19]
- Known allergy to sympathomimetic amines
Pregnancy: The phentermine/topiramate combination (Qsymia) is absolutely contraindicated in pregnancy due to topiramate's risk of birth defects, enforced through a mandatory safety programme.[11] No controlled data exist for phentermine alone in pregnancy; it is presumed unsafe.safety citation needed
Nursing: Whether phentermine passes into breast milk has not been determined; use during breastfeeding is contraindicated.[3]
Harm Reduction[edit]
Forms & Identification
Phentermine is a prescription pharmaceutical available in standardised tablet and capsule formulations from regulated manufacturers. The primary identification concern is product authenticity rather than adulterant contamination — counterfeit or diverted phentermine tablets circulate in some markets, particularly online, and may contain incorrect doses, substituted active ingredients, or no active ingredient at all. Tablets obtained outside of a verified pharmacy supply chain should be treated with caution.
Guidelines
- Take phentermine in the morning to reduce insomnia risk
- Maintain adequate fluid intake — stimulant effects and appetite suppression can mask dehydration
- Eat regular meals despite reduced appetite; prolonged caloric restriction without nutritional planning carries its own health risks
- Do not increase the dose if appetite suppression weakens — tolerance is expected and dose escalation increases cardiovascular risk without restoring effectiveness
- Avoid caffeine and other stimulants, which compound cardiovascular strain
- Monitor resting heart rate and blood pressure periodically, especially during the first weeks of use
- Do not crush or chew extended-release formulations
Set & Setting
Phentermine is a sustained stimulant with a half-life of 16–31 hours. Morning dosing is standard clinical practice to minimise insomnia — taking the dose after midday substantially increases the risk of sleep disruption. The stimulant effects are mild and functional; no special environmental preparation is required beyond ensuring adequate hydration and planning for reduced appetite throughout the day.
Aftercare & integration. After stopping phentermine — whether at the end of a prescribed course or due to tolerance — the primary challenge is appetite rebound effect. Hunger signals that were suppressed during treatment return, often intensely. Planning nutritional strategies and behavioural approaches to eating before discontinuation helps prevent rapid weight regain.
Sleep disruption may linger for several days after the last dose given the drug's long half-life. Maintaining consistent sleep schedules and avoiding caffeine during the washout period supports recovery of normal sleep patterns. Fatigue and low energy in the first week off phentermine are common and typically self-limiting.
Recovery & Support
Phentermine dependence is uncommon, but psychological reliance on appetite suppression can develop — particularly when the drug is used as a sole weight-management strategy without dietary or behavioural change. If stopping phentermine feels unmanageable, or if doses have been escalated beyond prescription, professional support is appropriate.
Resources include prescribing physicians (who can supervise tapering if needed), registered dietitians for nutritional transition planning, and SAMHSA's National Helpline (1-800-662-4357) for substance use concerns. Cognitive behavioural therapy has established efficacy for both weight management and stimulant use disorders.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: chest pain, severe headache, rapid or irregular heartbeat, confusion, seizures, body temperature hot to the touch through clothing, or loss of consciousness. These distinguish a medical emergency from ordinary stimulant side effects like mild restlessness or dry mouth.
Immediate steps:
- 1. Call emergency services (911 in the US)
- 2. Do not administer more phentermine or other stimulants
- 3. If the person is conscious and overheating, move to a cool environment and apply cool water to skin
- 4. If unconscious but breathing, place in the recovery position
- 5. Do not induce vomiting
- 6. Do not administer beta-blockers — they may worsen the situation
What to tell the dispatcher: The substance (phentermine), approximate dose and time taken, any other medications or substances used, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Phentermine occupies a distinctive regulatory position: continuously approved in the United States since 1959, yet withdrawn or banned across most of Europe since 2000–2001. This transatlantic divergence reflects differing risk–benefit assessments following the fen-phen crisis. In jurisdictions where it remains available, phentermine is universally classified as a controlled substance requiring a prescription.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | FDA-approved 1959; phentermine monotherapy (Adipex-P, Lomaira) and combination (Qsymia) both marketed. Qsymia subject to REMS.[11] |
| Canada | Schedule IV (CDSA) | Available by prescription. |
| Australia | Approved (TGA) | Marketed as Duromine (phentermine resin capsules); prescription required. |
| New Zealand | Approved | Available as Duromine; prescription required. |
| United Kingdom | Withdrawn | MHRA withdrew marketing authorisation circa 2000.[25] |
| European Union | Banned | European Commission decision March 2000; effective April 2001. EMA rejected PHEN/TPM (Qsiva) in 2012 and 2013.[25] |
| Germany | Withdrawn | Marketing authorisation withdrawn as part of EU-wide action.[13] |
| Sweden | Banned | Controlled substance; not marketed.[25] |
| Turkey | Banned | Not available.[25] |
Drug testing: Phentermine produces positive results on standard amphetamine immunoassay urine drug screens. Confirmatory testing (GC-MS or LC-MS/MS) is required to distinguish phentermine from methamphetamine or amphetamine.[13] Prescription holders should disclose phentermine use to drug testing facilities to avoid false-positive interpretation.
Phentermine monotherapy does not carry a REMS requirement in the United States.[11] The REMS programme applies only to the Qsymia (PHEN/TPM ER) formulation, designed to prevent pregnancy exposure to topiramate.
references
- [1]
- [2] ^abcRothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin — Synapse PMID:11071707
- [3]
- [4] ^abcdConnolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine — New England Journal of Medicine PMID:9271479
- [5] ^abcAlexander M, Rothman RB, Baumann MH, et al. (2005) Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis — Synapse PMID:15729739
- [6] ^abHendricks EJ, Greenway FL (2011) A study of abrupt phentermine cessation in patients in a weight management program — American Journal of Therapeutics doi:10.1097/mjt.0b013e3181d070d7